The near-term binary catalyst is the ABTECT Phase 3 UC maintenance top-line data, expected within ~4-6 weeks. Positive data would de-risk NDA submission pathway and likely drive a re-rating. Failure would significantly impair the asset's value. The cash position through Q4 2027 is sufficient to cover ongoing operations and clinical programs through key milestones, including the Phase 3 readout.
Price Chart
Executive Summary
Abivax reported Q1 2026 net loss of €48.5M (vs €52.4M loss in Q1 2025) with operating loss of €56.2M. The press release highlights durable Phase 2 clinical remission data (68% at week 144 on 25mg de-escalation) and €491.6M cash runway into Q4 2027. The company is pre-revenue with a biotech pipeline catalyst — the ABTECT Phase 3 UC maintenance trial top-line results due late Q2 2026 is the near-term binary event.
Key Facts
- Operational loss of €56.2M in Q1 2026 vs €47.2M in Q1 2025
- Net loss of €48.5M vs €52.4M year-over-year (improved by financial gain)
- Cash, cash equivalents and short-term investments of €491.6M as of March 31, 2026
- Cash runway projected into Q4 2027
- Phase 3 ABTECT-UC maintenance trial top-line results expected late Q2 2026
- 130 patients de-escalated to 25mg obefazimod; 68% in clinical remission at week 144 (ITT)
- NDA submission for obefazimod in UC planned for Q4 2026 (subject to positive data)
- Phase 2b CD induction trial top-line results expected Q4 2026
- R&D spend increased 26% YoY to €49.5M, driven by new indications and CD program
- Equity offering of $45M (€38.5M) ADS completed May 5, 2026
Financial Impact
Pre-revenue clinical biotech — no revenue to evaluate. Q1 2026 operating loss €56.2M vs €47.2M in Q1 2025; net loss improved by financial gain (€8.0M vs -€5.2M). Cash burn from operations was €50.5M in Q1 2026 vs €33.3M in Q1 2025.
Risk Factors
- Phase 3 ABTECT-UC maintenance trial may fail to meet endpoints — binary risk for the stock near-term
- Pre-revenue stage with high cash burn rate (€50.5M operating cash outflow in Q1 2026)
- Dilution risk from ADS offering completed May 5, 2026 ($45M)
- Regulatory and commercial execution risk for obefazimod in UC and CD indications
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3300344 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 6, 2026 8w ago | Institutional Cluster | $130.00 $114.04 | ▼ −12.28% | ▼ −12.88% | $94.17 (−27.56%) |
Jul 2, 2026 13w ago | 6-K | $144.65 $124.33 | ▲ +14.05% | ▲ +13.63% | $94.17 (+34.90%) |
Jul 2, 2026 13w ago | 424B5 | $144.65 $124.33 | ▲ +14.05% | ▲ +13.63% | $94.17 (+34.90%) |
Jul 1, 2026 13w ago | Press Release | $132.56 $118.84 | ▲ +10.35% | ▲ +8.16% | $94.17 (+28.96%) |
Jun 29, 2026 13w ago | 6-K | $133.26 $128.00 | ▼ −3.95% | ▼ −2.92% | $94.17 (−29.33%) |
Jun 29, 2026 13w ago | Press Release | $133.26 $128.00 | ▼ −3.95% | ▼ −2.92% | $94.17 (−29.33%) |
May 22, 2026 18w ago | Press Release | $126.41 $94.01 | ▼ −25.63% | ▼ −23.68% | $94.17 (−25.50%) |
Mar 23, 2026 27w ago | Press Release | $110.17 $115.99 | ▲ +5.28% | ▼ −3.62% | $94.17 (−14.52%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access